Trending

biosimilars

Boehringer Ingelheim axes biosimilars development outside US

Boehringer Ingelheim axes biosimilars development outside US

Boehringer Ingelheim has said it has axed ex-US development of its biosimilars, focusing instead on getting its Humira

X

Boehringer Ingelheim axes biosimilars development outside US

https://pharmaphorum.com/news/boehringer-ingelheim-axes-biosimilars-development-outside-us/

NHS saving £300m with Humira biosimilar deal

NHS saving £300m with Humira biosimilar deal

The NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of

X

NHS saving £300m with Humira biosimilar deal

https://pharmaphorum.com/news/nhs-saving-300m-with-humira-biosimilar-deal/

Mundipharma’s Neulasta biosimilar approved in EU

Mundipharma’s Neulasta biosimilar approved in EU

A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU

X

Mundipharma’s Neulasta biosimilar approved in EU

https://pharmaphorum.com/news/mundipharmas-neulasta-biosimilar-approved-in-eu/

Mundipharma appoints former GSK exec as CFO

Mundipharma appoints former GSK exec as CFO

The Mundipharma network of independent pharma companies has appointed Arnaud Breabout as chief financial officer. Breabout was most

X

Mundipharma appoints former GSK exec as CFO

https://pharmaphorum.com/news/mundipharma-appoints-former-gsk-exec-as-cfo/

J+D, Pharma Forecasting Experts Partner with Epiphany, Oncology Data Experts

J+D have brought several innovations to market this year including Online Training, theHub, and FC+ software. Onco+ is

X

J+D, Pharma Forecasting Experts Partner with Epiphany, Oncology Data Experts

https://pharmaphorum.com/partner-content/jd-pharma-forecasting-experts-partner-with-epiphany-oncology-data-experts/

Javaad Asghari joins J+D from Global Data

Javaad Asghari joins J+D from Global Data

Javaad joins J+D from Global Data

X

Javaad Asghari joins J+D from Global Data

https://pharmaphorum.com/partner-content/javaad-asgahri-joins-jd-from-global-data/

J+D Pharma Forecasting Workshop – Zurich

J+D Pharma Forecasting Workshop – Zurich

J+D Interactive Pharma Forecasting Workshop

X

J+D Pharma Forecasting Workshop – Zurich

https://jdforecasting.com/training/multi-client/

Has the NHS joined the biosimilars revolution?

Has the NHS joined the biosimilars revolution?

Biosimilars have cut the price of biologic drugs by up to 80% on the NHS, according to Paul

X

Has the NHS joined the biosimilars revolution?

https://pharmaphorum.com/oncology/nhs-joined-biosimilar-revolution/

Samsung Bioepis’ Humira biosimilar launches in EU

Samsung Bioepis’ Humira biosimilar launches in EU

Samsung Bioepis has become the latest biosimilars company to confirm it has launched a cheaper near-copy of AbbVie’s

X

Samsung Bioepis’ Humira biosimilar launches in EU

https://pharmaphorum.com/news/samsung-bioepis-humira-biosimilar-launches-in-eu/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com